CHMP recommend licence extension for catridecacog (NovoThirteen)

The CHMP have recommended that the licensed use of treatment can be extended to include the treatment of breakthrough bleeding episodes during regular prophylaxis in congenital factor XIII A-subunit deficiency.

Source:

European Medicines Agency